<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin J Pain</journal-id><journal-id journal-id-type="iso-abbrev">Clin J Pain</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The Clinical journal of pain</journal-title></journal-title-group><issn pub-type="ppub">0749-8047</issn><issn pub-type="epub">1536-5409</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10210068</article-id><article-id pub-id-type="pmcid-ver">PMC10210068.1</article-id><article-id pub-id-type="pmcaid">10210068</article-id><article-id pub-id-type="pmcaiid">10210068</article-id><article-id pub-id-type="manuscript-id">NIHMS1860374</article-id><article-id pub-id-type="pmid">36728675</article-id><article-id pub-id-type="doi">10.1097/AJP.0000000000001093</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1860374</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1860374</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparative study of opioid initiation with tramadol, short-acting hydrocodone or short-acting oxycodone on opioid-related adverse outcomes among chronic non-cancer pain subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Acharya</surname><given-names initials="M">Mahip</given-names></name><degrees>B.S</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hayes</surname><given-names initials="CJ">Corey J.</given-names></name><degrees>PharmD, PhD</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="C">Chenghui</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Painter</surname><given-names initials="JT">Jacob T.</given-names></name><degrees>PharmD, PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dayer</surname><given-names initials="L">Lindsey</given-names></name><degrees>PharmD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="BC">Bradley C.</given-names></name><degrees>PharmD, PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas</aff><aff id="A2"><label>2</label>Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas</aff><aff id="A3"><label>3</label>Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare Systems, North Little Rock, Arkansas</aff><aff id="A4"><label>4</label>College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas</aff><author-notes><corresp id="CR1">Corresponding Author Bradley C Martin, PharmD, PhD, Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Rahn Building, Room 6259, 4301 W. Markham Street, slot 522, Little Rock, AR-72205, <email>bmartin@uams.edu</email>, <bold>Phone:</bold> (501) 603-1992</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>01</day><month>3</month><year>2023</year></pub-date><volume>39</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">436512</issue-id><fpage>107</fpage><lpage>118</lpage><pub-history><event event-type="nihms-submitted"><date><day>27</day><month>04</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 12:25:14.010"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1860374.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P1">To compare the safety profiles of low- and high-dose tramadol, short-acting hydrocodone and short-acting oxycodone therapies among chronic non-cancer pain individuals.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">A retrospective cohort study of individuals with back/neck pain/osteoarthritis with an initial opioid prescription for tramadol, hydrocodone or oxycodone was conducted using IQVIA PharMetrics<sup>&#174;</sup> Plus claims for Academics database (2006&#8211;2020). Two cohorts were created for separately studying opioid-related adverse events (overdoses, accidents, self-inflicted injuries and violence-related injuries) and substance use disorders (opioid and non-opioid). Subjects were followed from the index date until an outcome event, end of enrollment or data end. Time-varying exposure groups were constructed and Cox regression models estimated.</p></sec><sec id="S3"><title>Results:</title><p id="P3">A total of 1,062,167 [tramadol (16.5%), hydrocodone (61.1%), oxycodone (22.4%)] and 986,809 [tramadol (16.5%), hydrocodone (61.3%), oxycodone (22.2%)] individuals were in the adverse event and substance use disorder cohorts. All high-dose groups had elevated risk of nearly all outcomes, compared to low-dose hydrocodone. Compared to low-dose hydrocodone, low-dose oxycodone was associated with a higher risk of opioid overdose (HR: 1.79 (1.37&#8211;2.33)). No difference in risk was observed between low-dose tramadol and low-dose hydrocodone (HR: 0.85 (0.64&#8211;1.13)). Low-dose oxycodone had higher risks of opioid use disorder, and low-dose tramadol had lower risk of accidents, self-inflicted injuries and opioid use disorder compared to low-dose hydrocodone.</p></sec><sec id="S4"><title>Discussion:</title><p id="P4">Low-dose oxycodone had higher risk of opioid-related adverse outcomes compared to low-dose tramadol and hydrocodone. This should be interpreted in conjunction with the benefits of pain control and functioning associated with oxycodone use in future research.</p></sec></abstract><kwd-group><kwd>tramadol</kwd><kwd>hydrocodone</kwd><kwd>oxycodone</kwd><kwd>overdose</kwd><kwd>opioid use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>